Results 51 to 60 of about 18,044 (151)
Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. [PDF]
Transforming growth factor-ß (TGF-ß) signaling is implicated in the pathogenesis of fibrosis in scleroderma or systemic sclerosis (SSc), but the precise mechanisms are poorly understood. The immediate-early gene Egr-1 is an inducible transcription factor
Swati Bhattacharyya +7 more
doaj +1 more source
Silicone breast implants are presented as a model system for understanding polymer permeation in vivo. Rather than representing material failure, “gel bleed” emerges from solution–diffusion transport‐mediated. By integrating polymer architecture, physicochemical transport, and biointerfacial processes, this review provides a unified framework that ...
D. Bouyer +12 more
wiley +1 more source
Objective Interstitial lung disease (ILD) is an important extra‐articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung ...
Marie Vermant +15 more
wiley +1 more source
Background: Systemic sclerosis is a multi-systemic autoimmune disorder characterised by the generation of autoantibodies, massive deposition of collagen and other matrix substances in the connective tissues and alterations of the microvasculature ...
Oguntona SA, Olatunde OA, Bakare BO
doaj
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
A clinical case of a patient with systemic scleroderma who underwent COVID-19. In systemic scleroderma, pulmonary involvement is the most common cause of death in patients is presented.
E. A. Akhmetov +2 more
doaj +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken +7 more
wiley +1 more source
Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio +15 more
wiley +1 more source
Objective Systemic sclerosis (SSc) is associated with an increased risk of cancer. We aimed to assess the prevalence of cancer in our cohort and to explore possible associations with clinical, immunological and treatment characteristics.Methods Our ...
Maria De Santis +8 more
doaj +1 more source

